<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515566</url>
  </required_header>
  <id_info>
    <org_study_id>2011-1007</org_study_id>
    <nct_id>NCT01515566</nct_id>
  </id_info>
  <brief_title>Breakthrough Dyspnea Fentanyl Study in Cancer Patients</brief_title>
  <official_title>Effects of Prophylactic Subcutaneous Fentanyl on Exercise-Induced Breakthrough Dyspnea in Cancer Patients: A Preliminary Double-Blind, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if fentanyl given under the skin can
      reduce shortness of breath in cancer patients. Researchers also want to learn if it can help
      to improve your physical function. In this study, fentanyl will be compared to a placebo.

      Fentanyl is commonly used for treatment of cancer pain. It is believed to help patients with
      their shortness of breath as well.

      A placebo is not a drug. It looks like the study drug but is not designed to treat any
      disease or illness. It is designed to be compared with a study drug to learn if the study
      drug has any real effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the flip of a coin) to either receive fentanyl or placebo. You will have an equal chance
      of being assigned to either group.

      Study Drug/Placebo Administration:

      Before you receive the study drug/placebo, you will walk back and forth in an indoor corridor
      for up to 6 minutes. You may feel out of breath or become exhausted. You may slow down, stop,
      and rest at any time you need to.

      After that, you will sit down and rest (for up to 1 hour). During this time, the study
      drug/placebo will be prepared.

      You will then be given a study drug/placebo shot under the skin in your arms or legs. You
      will then wait for another 15 minutes and repeat the walking test.

      Study Visit:

      During your study visit, the study staff will collect information from your medical record
      about your age, sex, race, disease type, how well you are able to perform the normal
      activities of daily living, any drugs you are taking, and possible causes of shortness of
      breath.

      You will also complete 2 walking tests. Before the walk tests, you will complete 2
      questionnaires. One (1) of them asks about any breathing symptoms you may be having, and the
      other asks about any other symptoms you may be having. It should take about 10 minutes to
      complete these questionnaires.

      Before and after each walk test, the study staff will record your heart rate, breathing rate,
      and the level of air breathed out using a measuring device that will be clipped onto your
      finger. The study staff will also ask you questions about how hard it is to catch your breath
      and your level of tiredness.

      During each walk test, you will be asked about how hard it is to catch your breath. The
      distance you walked and how often and for how long you stopped will be recorded. Before and
      after the second walk test, the study staff will ask you about any side effects from the
      study drug/placebo that you may be having.

      During the rest period between the 2 walk tests, you may be asked how hard it is to catch
      your breath several times.

      At the end of the study visit, you will fill out 1 questionnaire that asks if you think the
      study drug/placebo is helping you, and how satisfied you are with the study. It should take
      about 5 minutes to complete the questionnaire.

      Length of Study:

      You will be on this study for up to 100 minutes.You will be taken off study if intolerable
      side effects occur during the study.

      This is an investigational study. Fentanyl is FDA approved and commercially available for the
      treatment of pain. It's use to help with shortness of breath is investigational.

      Up to 20 patients will be enrolled in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention Rate</measure>
    <time_frame>Baseline to study completion, up to 100 minutes.</time_frame>
    <description>Retention rate is defined as the percentage of subjects able to complete the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Fentanyl Versus Placebo for Exercise-Induced and Breakthrough Dyspnea</measure>
    <time_frame>Baseline to 100 minutes for study participation.</time_frame>
    <description>Participants receive either Fentanyl subcutaneous (SQ) 15 minutes before walking test, or Placebo (SQ) 15 minutes before walking test. During the study, trained research staff perform study assessments and monitor participant carefully throughout the study period. Six-minute walk tests were carried out following guidelines from the American Thoracic Society. The intensity of dyspnea at 0, 1, 2, 3, 4, 5 and 6 minute of each walk test were assessed using a validated numeric rating scale (NRS) ranging from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;) and every 5 minutes during the rest period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Fentanyl on Walk Distance</measure>
    <time_frame>Baseline 6 minute walk test (6MWT) to second 6MWT, up to 100 minutes for study participation.</time_frame>
    <description>Ambulatory patients with breakthrough dyspnea performed a baseline 6 minute walk test (6MWT), and then received either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. The change in walk distance was documented between the first and second 6MWT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Advanced Cancers</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fentanyl subcutaneously (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test, and 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal saline 0.9% preservative free SQ 15 minutes before walk test, and 6 minute walk test at baseline and 15 minutes after Placebo. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.</description>
    <arm_group_label>Fentanyl</arm_group_label>
    <other_name>Sublimaze</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline 0.9% preservative free SQ 15 minutes before walk test.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Walking Tests</intervention_name>
    <description>6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.</description>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.</description>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Surveys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of cancer

          2. Breakthrough dyspnea, defined in this study as dyspnea on exertion with an average
             intensity level &gt;=3/10 on the numeric rating scale

          3. Outpatient or inpatient at MD Anderson Cancer Center seen by the Supportive Care or
             Rehabilitation Service

          4. Able to communicate in English or Spanish

          5. Ambulatory and able to walk with or without walking aid

          6. On strong opioids with morphine equivalent daily dose of 30-580 mg, with stable (i.e.
             +/- 30%) regular dose over the last 24 hours

          7. Karnofsky performance status &gt;=50%

          8. Age 18 or older

        Exclusion Criteria:

          1. Dyspnea at rest &gt;=7/10 at the time of enrollment

          2. Supplemental oxygen requirement &gt;6 L per minute

          3. Delirium (i.e. Memorial delirium rating scale &gt;13)

          4. History of unstable angina or myocardial infarction 1 month prior to study enrollment

          5. Resting heart rate &gt;120 at the time of study enrollment

          6. Systolic pressure &gt;180 mmHg or diastolic pressure &gt;100 mmHg at the time of study
             enrollment

          7. History of active substance abuse within the past 12 months

          8. History of allergy to fentanyl

          9. Unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <results_first_submitted>August 7, 2014</results_first_submitted>
  <results_first_submitted_qc>August 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2014</results_first_posted>
  <last_update_submitted>August 7, 2014</last_update_submitted>
  <last_update_submitted_qc>August 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancer</keyword>
  <keyword>Dyspnea</keyword>
  <keyword>Exercise-induced breakthrough dyspnea</keyword>
  <keyword>Shortness of breath</keyword>
  <keyword>Fentanyl</keyword>
  <keyword>Sublimaze</keyword>
  <keyword>Placebo</keyword>
  <keyword>Normal saline</keyword>
  <keyword>NS</keyword>
  <keyword>Questionnaires</keyword>
  <keyword>Surveys</keyword>
  <keyword>Walk test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Outpatient participants from the Supportive Care Center at MD Anderson Cancer Center were recruited between July 10, 2012 and December 12, 2012.</recruitment_details>
      <pre_assignment_details>Six participants of the 26 recruited were excluded from the trial before assignment to groups due to ineligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fentanyl</title>
          <description>Fentanyl subcutaneous (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test; 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Questionnaires completed at baseline and after study visit.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Normal saline 0.9% preservative free SQ 15 minutes before walk test; 6 minute walk test (6MWT) at baseline and 15 minutes after Placebo. Questionnaires completed at baseline and after study visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fentanyl</title>
          <description>Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test; 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl or Placebo. Questionnaires completed at baseline and after study visit.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal saline 0.9% preservative free SQ 15 minutes before walk test; 6MWT at baseline and 15 minutes after Fentanyl or Placebo. Questionnaires completed at baseline and after study visit.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Fentanyl Versus Placebo for Exercise-Induced and Breakthrough Dyspnea</title>
        <description>Participants receive either Fentanyl subcutaneous (SQ) 15 minutes before walking test, or Placebo (SQ) 15 minutes before walking test. During the study, trained research staff perform study assessments and monitor participant carefully throughout the study period. Six-minute walk tests were carried out following guidelines from the American Thoracic Society. The intensity of dyspnea at 0, 1, 2, 3, 4, 5 and 6 minute of each walk test were assessed using a validated numeric rating scale (NRS) ranging from 0 (“no shortness of breath”) to 10 (“worst possible shortness of breath”) and every 5 minutes during the rest period.</description>
        <time_frame>Baseline to 100 minutes for study participation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fentanyl</title>
            <description>Fentanyl SQ dose equivalent to 15-25% of MEDD 15 minutes before walk test; 6MWT at baseline and 15 minutes after Fentanyl.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline 0.9% preservative free SQ 15 minutes before walk test; 6MWT at baseline and 15 minutes after Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Fentanyl Versus Placebo for Exercise-Induced and Breakthrough Dyspnea</title>
          <description>Participants receive either Fentanyl subcutaneous (SQ) 15 minutes before walking test, or Placebo (SQ) 15 minutes before walking test. During the study, trained research staff perform study assessments and monitor participant carefully throughout the study period. Six-minute walk tests were carried out following guidelines from the American Thoracic Society. The intensity of dyspnea at 0, 1, 2, 3, 4, 5 and 6 minute of each walk test were assessed using a validated numeric rating scale (NRS) ranging from 0 (“no shortness of breath”) to 10 (“worst possible shortness of breath”) and every 5 minutes during the rest period.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dyspnea at 0 minutes (Baseline walk test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="1" lower_limit="1.8" upper_limit=".4"/>
                    <measurement group_id="O2" value="3" spread="3" lower_limit="1.5" upper_limit=".1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea at 6 minutes (Baseline walk test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="1" lower_limit="3.2" upper_limit=".4"/>
                    <measurement group_id="O2" value="7" spread="3" lower_limit="4" upper_limit=".02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea at 0 minutes (Second walk test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1" lower_limit="1.8" upper_limit=".04"/>
                    <measurement group_id="O2" value="2" spread="2" lower_limit="1.5" upper_limit=".1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea at 6 minutes (Second walk test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1" lower_limit="3.2" upper_limit=".4"/>
                    <measurement group_id="O2" value="5" spread="3" lower_limit="4" upper_limit=".02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retention Rate</title>
        <description>Retention rate is defined as the percentage of subjects able to complete the study.</description>
        <time_frame>Baseline to study completion, up to 100 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fentanyl</title>
            <description>Fentanyl SQ dose equivalent to 15-25% of MEDD 15 minutes before walk test; 6MWT at baseline and 15 minutes after Fentanyl.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline 0.9% preservative free SQ 15 minutes before walk test; 6MWT at baseline and 15 minutes after Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Retention Rate</title>
          <description>Retention rate is defined as the percentage of subjects able to complete the study.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Fentanyl on Walk Distance</title>
        <description>Ambulatory patients with breakthrough dyspnea performed a baseline 6 minute walk test (6MWT), and then received either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. The change in walk distance was documented between the first and second 6MWT.</description>
        <time_frame>Baseline 6 minute walk test (6MWT) to second 6MWT, up to 100 minutes for study participation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fentanyl</title>
            <description>Fentanyl SQ dose equivalent to 15-25% of MEDD 15 minutes before walk test; 6MWT at baseline and 15 minutes after Fentanyl.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline 0.9% preservative free SQ 15 minutes before walk test; 6MWT at baseline and 15 minutes after Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Fentanyl on Walk Distance</title>
          <description>Ambulatory patients with breakthrough dyspnea performed a baseline 6 minute walk test (6MWT), and then received either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. The change in walk distance was documented between the first and second 6MWT.</description>
          <units>feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Walk Distance (Baseline Walk Test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397.7" spread="98.1"/>
                    <measurement group_id="O2" value="399" spread="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walk Distance (Second Walk Test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="434.9" spread="95.4"/>
                    <measurement group_id="O2" value="417.9" spread="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse effect collection from baseline up to 100 minutes for study participation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fentanyl</title>
          <description>Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test. 6 minute walk test at baseline and 15 minutes after Fentanyl.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Normal saline 0.9% preservative free SQ 15 minutes before walk test. 6 minute walk test at baseline and 15 minutes after Placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain with subcutaneous injection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small sample size means findings are susceptible to random errors and regression to the mean.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Hui, MD, MSc, FRCPC / Asst. Professor, Palliative Care and Rehabilitation Medicine</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-6085</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

